These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 29756563)

  • 21. Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach.
    P JJ; Manju SL; Ethiraj KR; Elias G
    Eur J Pharm Sci; 2018 Aug; 121():356-381. PubMed ID: 29883727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress in COX-2 inhibitors: a journey so far.
    Chakraborti AK; Garg SK; Kumar R; Motiwala HF; Jadhavar PS
    Curr Med Chem; 2010; 17(15):1563-93. PubMed ID: 20166930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
    Meyer-Kirchrath J; Schrör K
    Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
    Hayashi S; Ueno N; Murase A; Nakagawa Y; Takada J
    Eur J Med Chem; 2012 Apr; 50():179-95. PubMed ID: 22373734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications.
    Pairet M; Engelhardt G
    Fundam Clin Pharmacol; 1996; 10(1):1-17. PubMed ID: 8900495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cyclooxygenase-2: a new therapeutic target in atherosclerosis?].
    Páramo JA; Beloqui O; Orbe J
    Med Clin (Barc); 2006 May; 126(20):782-6. PubMed ID: 16792983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications.
    Aïd S; Bosetti F
    Biochimie; 2011 Jan; 93(1):46-51. PubMed ID: 20868723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
    Hersh EV; Lally ET; Moore PA
    Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic potential of COX-2 inhibitors in arthritis.
    Jackson CG
    Expert Opin Investig Drugs; 2001 Jul; 10(7):1317-25. PubMed ID: 11772254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting inhibition of COX-2: a review of patents, 2002-2006.
    da Cunha EF; Ramalho TC; Josa D; Caetano MS; de Souza TC
    Recent Pat Inflamm Allergy Drug Discov; 2007 Jun; 1(2):108-23. PubMed ID: 19075973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic pharmacological approach to the characterization of NSAIDs.
    Lora M; Denault JB; Leduc R; de Brum-Fernandes AJ
    Prostaglandins Leukot Essent Fatty Acids; 1998 Jul; 59(1):55-62. PubMed ID: 9758208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of cyclooxygenase inhibitors on bone and cartilage metabolism--a review.
    Nwadinigwe CU; Anyaehie UE
    Niger J Med; 2007; 16(4):290-4. PubMed ID: 18080582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E
    Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases.
    Minghetti L
    J Neuropathol Exp Neurol; 2004 Sep; 63(9):901-10. PubMed ID: 15453089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].
    Mateos JL
    Drugs Today (Barc); 2010 Feb; 46 Suppl A():1-25. PubMed ID: 20224826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclooxygenase-2: a therapeutic target.
    Turini ME; DuBois RN
    Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.
    Celotti F; Durand T
    Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):147-62. PubMed ID: 14518558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.
    Waterbury LD; Silliman D; Jolas T
    Curr Med Res Opin; 2006 Jun; 22(6):1133-40. PubMed ID: 16846546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.
    Sarkar FH; Adsule S; Li Y; Padhye S
    Mini Rev Med Chem; 2007 Jun; 7(6):599-608. PubMed ID: 17584158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1,5-diarylpyrazole derivatives.
    Abdellatif KR; Fadaly WA; Ali WA; Kamel GM
    J Enzyme Inhib Med Chem; 2016; 31(sup3):54-60. PubMed ID: 27541738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.